Proamanullin: Difference between revisions

Jump to navigation Jump to search
(New page: {{SI}} {{EH}} {{chembox |ImageFile=Proamanullin structure.png |ImageSize=200px |ImageFile1=Proamanullin 3d chemical structure.png |ImageSize1=200px |IUPACName= |OtherNames=2-L-Proline-3-i...)
 
m (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +))
 
Line 37: Line 37:


==References==
==References==
{{reflist}}
{{reflist|2}}


==See also==
==See also==

Latest revision as of 14:02, 6 September 2012

WikiDoc Resources for Proamanullin

Articles

Most recent articles on Proamanullin

Most cited articles on Proamanullin

Review articles on Proamanullin

Articles on Proamanullin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Proamanullin

Images of Proamanullin

Photos of Proamanullin

Podcasts & MP3s on Proamanullin

Videos on Proamanullin

Evidence Based Medicine

Cochrane Collaboration on Proamanullin

Bandolier on Proamanullin

TRIP on Proamanullin

Clinical Trials

Ongoing Trials on Proamanullin at Clinical Trials.gov

Trial results on Proamanullin

Clinical Trials on Proamanullin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Proamanullin

NICE Guidance on Proamanullin

NHS PRODIGY Guidance

FDA on Proamanullin

CDC on Proamanullin

Books

Books on Proamanullin

News

Proamanullin in the news

Be alerted to news on Proamanullin

News trends on Proamanullin

Commentary

Blogs on Proamanullin

Definitions

Definitions of Proamanullin

Patient Resources / Community

Patient resources on Proamanullin

Discussion groups on Proamanullin

Patient Handouts on Proamanullin

Directions to Hospitals Treating Proamanullin

Risk calculators and risk factors for Proamanullin

Healthcare Provider Resources

Symptoms of Proamanullin

Causes & Risk Factors for Proamanullin

Diagnostic studies for Proamanullin

Treatment of Proamanullin

Continuing Medical Education (CME)

CME Programs on Proamanullin

International

Proamanullin en Espanol

Proamanullin en Francais

Business

Proamanullin in the Marketplace

Patents on Proamanullin

Experimental / Informatics

List of terms related to Proamanullin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Template:Chembox E numberTemplate:Chembox Appearance
Proamanullin
File:Proamanullin structure.png
File:Proamanullin 3d chemical structure.png
Names
Other names
2-L-Proline-3-isoleucine-alpha-amanitin
Identifiers
3D model (JSmol)
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
Properties
C39H54N10O11S
Molar mass 870.97 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Promanullin is a cyclic nonribosomal peptide. It is an amatoxin, all of which are found in several members of the Amanita genus of mushrooms.

Toxicology

Like other amatoxins, proamanullin is an inhibitor of RNA polymerase II. Promanullin has a specific attraction to the enzyme RNA polymerase II. Upon ingestion, it binds to the RNA polymerase II enzyme, effectively causing cytolysis of hepatocytes (liver cells).[1]

References

  1. Cochet-Meilhac M, Chambon P (1974). "Animal DNA-dependent RNA polymerases. 11. Mechanism of the inhibition of RNA polymerases B by amatoxins". Biochim. Biophys. Acta. 353 (2): 160–84. PMID 4601749. Unknown parameter |month= ignored (help)

See also

External links

Template:SIB

Template:WH Template:WS